Table 2. Demographic and clinic characteristics, treatment, serology and surface gene mutations in the 8 cases with 145R mutation.

Case	Age(yr)/sex	Race	Genotype	HBV DNA level (UI/mL)	ALT (UI/mL)/bilirubin (mg/dL)*	Treatment	HBsAg detection, by immunoassay kits					HBsAg mutations
							EIAgen	AxSYM	Architect	Vitros	Monolisa Ultra
1	88/Male	Caucasian	D	1.7x107	121/0.66	No	negative	positive	positive	negative	negative	G145R, T126I, T131A, C139Y, E/D144G
2	56/Male	Caucasian	A	2.4x104	47/1.52	Yes	negative	positive	positive	negative	negative	G145R, T126I, M133L
3	38/Female	Caucasian	D	1.6x106	562/4.8	No	positive	positive	positive	positive	positive	G145R
4	60/Female	Caucasian	D	4.4x103	11/0.27	No	positive	positive	positive	positive	positive	G145R
5	74/Male	Caucasian	D	8.2x104	84/0.65	No	positive	positive	positive	positive	positive	G145R
6	51/Male	Caucasian	D	4.2x103	324/0.48	No	negative	positive	positive	negative	negative	G145R, P120Q, T126I
7	55/Male	African	D	6.7x106	15/0.4	No	positive	positive	positive	positive	positive	G145A
8	40/Male	Caucasian	C	3.0x101	33/1.41	Yes	positive	positive	positive	positive	positive	G145R

*Alanine Aminotransferase level, reference range 0–40 U/L; total bilirubin reference range 0.4–1.2 mg/dL.